Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glesatinib + docetaxel
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Glesatinib (MGCD265) in combination with docetaxel is an investigational therapeutic regimen developed by Mirati Therapeutics for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC). Glesatinib is an orally bioavailable, small molecule multi-kinase inhibitor that targets the MET and AXL receptor tyrosine kinases, which are often implicated in tumor growth, invasion, and resistance to therapy. It also exhibits activity against the VEGFR and PDGFR families. Docetaxel is a taxane-based cytotoxic chemotherapy agent that promotes the assembly of tubulin into stable microtubules and inhibits their disassembly, leading to cell cycle arrest and apoptosis. The combination was studied in Phase I/II clinical trials to evaluate whether the dual inhibition of key signaling pathways and microtubule stabilization could provide enhanced clinical benefit in patients with advanced malignancies.
- Other names
- glesatinib + docetaxelMGCD265 + docetaxel
02
Targets
DDR2 (Discoidin domain receptor tyrosine kinase 2)MET (Mesenchymal-epithelial transition factor receptor)Trk (Trk receptor family)TUBB (Tubulin (alpha and beta subunits))EPH (EPH receptor family)BCL-2 (BCL-2 family)PDGFR (PDGFR family)VEGFR (VEGFR family)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)AXL (AXL receptor tyrosine kinase)
Beyond the preview
Go deeper on glesatinib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glesatinib + docetaxel.